PRV-induced infertility is caused by decreased P4 level. by Bing-Qian Su (8616981)

Decreasing neural activity in MBONs that suppress PER when activated has modest effects. by Justine Chia (5459294)

Exposure to low CO₂ levels decreases ER cholesterol levels. by Nityanand Bolshette (17396845)

“…<b>(B)</b> Bioluminescence recordings from the different conditions as depicted in <b>(A)</b>, the arrow indicates the time CO₂ was shifted from 5% to 1% (mean ± SE, <i>n</i> = 4 biological replicates per condition, AUC for 0 mM 0.34 ± 0.007, 1.59 ± 0.004 (<i>P</i> < 0.0001), 0.5 mM 1.00 ± 0.023, 2.68 ± 0.04 (<i>P</i> < 0.0001), 1 mM 1.66 ± 0.07, 3.34 ± 0.04 (<i>P</i> < 0.0001), 3 mM 2.06 ± 0.02, 2.79 ± 0.07 (<i>P</i> < 0.0001), 5 mM 2.02 ± 0.05, 2.43 ± 0.06 (<i>P</i> < 0.002), 7 mM 1.85 ± 0.01, 1.77 ± 0.02 (<i>P</i> < 0.02) two-sided Student’s <i>t</i> test). …”

VPS34 inhibition decreases intracellular levels of cholesteryl-esters, blocks cholesterol uptake and enhances lysosomal degradation of LDLR. by Marek J. Kobylarz (9292599)

Cardiac-specific p38γ/δ^act overexpression decreases cardiac glycogen storage and lipid accumulation. by Ayelén M. Santamans (5487941)

The GluN2B-C456Y mutation decreases recombinant NMDAR currents and alters receptor properties. by Wangyong Shin (6793040)

“…<p>(A) The GluN2B-C456Y mutation strongly decreases diheteromeric GluN1/GluN2B NMDAR currents in <i>Xenopus</i> oocytes. …”

Scenario (6): Parameter variation (50% decrease)—With 5 N.m load applied at t = 0.3s. by Djaloul Karboua (16510091)

“…<p>Scenario (6): Parameter variation (50% decrease)—With 5 N.m load applied at t = 0.3s.…”

rHSP60 decreases LPS-induced mononuclear cell proliferation. by Igor Emiliano L. Souza (18196495)

Serum samples and 50% NAI values. Serum samples taken from CEIRS study. by Harrison Powell (9040128)

Adjusted analyses of the odds of a child aged 6–59 months being anaemic in Cambodia (N = 10,051). by Samnang Um (14990562)

Subjects:

GXM decreases the trans-endothelial electrical resistance (TEER) and transmigration of <i>C</i>. <i>neoformans</i> through HBECs in a blood brain barrier (BBB) model. by Hiu Ham Lee (15374677)

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

rHSP60 decreases viability of B lymphocyte cell line but not macrophage one. by Igor Emiliano L. Souza (18196495)

Mother-calf pairs differences among epidermis layers normalized to the mean of all three layers for δ¹³C and δ¹⁵N values. by Michelle Gelippi (9580022)

GSK343 decreased tumor stemness. by Laura V. Bownes (10276762)

“…Treatment with GSK343 significantly decreased tumorsphere formation by both the COA3 (A) and COA6 (B) cells, representing a decrease in stem cell-like phenotype. …”

HPD 1466 decreases empty capsid accumulation in cells replicating HBV. by Daniel P. Bradley (10306893)

Subjects:

GCase activity is significantly decreased in the brain and liver of the homozygous <i>GBA1</i> D409V KI mouse model at 4, 8, and 12 months of age. by Nicole K. Polinski (10947787)

“…In whole brain homogenate (A,C) and liver homogenate (B,D), GCase activity is significantly decreased in the <i>GBA1</i> D409V KI homozygous (HOM) mice as compared to C57Bl/6 wild type (WT) mice (n = 7/group). …”

Cellular co-infection decreases the potential for superinfection. by Brigitte E. Martin (8366847)

Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”